LD-2 disclosure · 2nd Quarter - Report
ADAPTIVE BIOTECHNOLOGIES
Client
- Description
- Biotechnology company focusing on immune-driven medicine
- Location
- Washington · United States of America
Registrant
- Description
- Law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesHealth Issues
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
LobbyistsKRISTINE BLACKWOOD · PARI MODY · EUGENIA PIERSON · CASEY BROUHARD · BOBBY MCMILLIN · KATIE BROWN · mr PETER ERIC DUYSHART
TargetedSENATE · HOUSE OF REPRESENTATIVES
Budget/Appropriations
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing.
LobbyistsKRISTINE BLACKWOOD · PARI MODY · EUGENIA PIERSON · CASEY BROUHARD · BOBBY MCMILLIN · KATIE BROWN · mr PETER ERIC DUYSHART
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
LobbyistsKRISTINE BLACKWOOD · PARI MODY · EUGENIA PIERSON · CASEY BROUHARD · BOBBY MCMILLIN · KATIE BROWN · mr PETER ERIC DUYSHART
SENATE · HOUSE OF REPRESENTATIVES